scispace - formally typeset
N

N.H. Gower

Researcher at University College London

Publications -  49
Citations -  3317

N.H. Gower is an academic researcher from University College London. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 20, co-authored 40 publications receiving 2724 citations. Previous affiliations of N.H. Gower include London Chest Hospital.

Papers
More filters
Journal ArticleDOI

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Nicholas McGranahan, +219 more
- 30 Nov 2017 - 
TL;DR: It is found that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity.
Journal ArticleDOI

Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life

TL;DR: In this paper, the authors describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.
Journal ArticleDOI

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Frederick Arce Vargas, +250 more
- 18 Apr 2017 - 
TL;DR: Use of an anti‐CD25 antibody with enhanced binding to activating Fc&ggr;Rs led to effective depletion of tumor‐infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors.
Journal ArticleDOI

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.

TL;DR: The survival benefit seen in this trial was entirely consistent with the NSCLC meta-analysis and subsequent similarly designed large trials, and the regimens used proved to be cost effective, the extra cost of chemotherapy being offset by longer survival.
Journal ArticleDOI

Five-Day Oral Etoposide Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous Chemotherapy

TL;DR: These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.